CIRM Funded Clinical Trials

Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies

Disease Area:

B cell cancers, Leukemia

Investigator:

Dr. David B. Miklos

Institution:

Stanford University

CIRM Grant:

CLIN2-10846 (Closed)

Award Value:

$11,034,982.00

Trial Sponsor:

Stanford University

Trial Stage:

Phase 1

Trial Status:

Active, not recruiting

Targeted Enrollment:

ClinicalTrials.gov ID:

NCT03233854

Details:

Chimeric Antigen Receptor (CAR) T Cell Therapy is an innovative cancer therapy with very encouraging response rates in patients. The therapy works by isolating a patient’s own T cells (a type of immune cell) and then genetically engineering them to recognize a protein on the surface of cancer cells, triggering their destruction. In some patients with B cell leukemias, however, cancer cells escape detection by the modified T cells and cause the cancer’s reoccurrence.

Researchers at the Stanford University School of Medicine have developed an engineered T cell designed to recognize not one, but two, cell surface proteins on cancer cells with the aim of enhancing a patient’s response to the therapy and reducing the potential for relapse. In addition, some of the T cells will form memory stem cells that will survive for years and continue to survey the body, killing any new or surviving cancer cells.

Design:

Open label, dose escalation study.

Goal:

Safety and feasibility.

News about this clinical trial:

Mackall awarded $11.9 million for anti-leukemia clinical trial